Martin Jädersten

About me
Publications
CV
Public outreach and news

About me

Martin Jädersten is an MD PhD who works 50% as a hematologist at Karolinska
University Hospital and 50% in translational research studying various
aspects of MDS.
He did a postdoc in Vancouver, Canada, working with second generation
sequencing in MDS and AML.

Research

He leads a national biobank project in MDS, aiming to collect samples from
all patients diagnosed with MDS in Sweden and performing a broad genetic
screen, linking genetics with clinical outcome. Other ongoing projects
include gene discovery using exome and whole genome sequencing, genetics of
leukemic transformation, and genetic determinants to response to growth
factor therapy in MDS.

Articles

Article: BLOOD. 2023;142(1):73-89

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option.

Dolinska M; Cai H; Månsson A; Shen J; Xiao P; Bouderlique T; Li X; Leonard E; Chang M; Gao Y; Medina JP; Kondo M; Sandhow L; Johansson A-S; Deneberg S; Söderlund S; Jädersten M; Ungerstedt J; Tobiasson M; Östman A; Mustjoki S; Stenke L; Le Blanc K; Hellström-Lindberg E; Lehmann S; Ekblom M; Olsson-Strömberg U; Sigvardsson M; Qian H
Article: LEUKEMIA. 2023;37(5):1103-1112

Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective.

Moreno Berggren D; Garelius H; Willner Hjelm P; Nilsson L; Rasmussen B; Weibull CE; Lambe M; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
Article: HAEMATOLOGICA. 2023;108(4):1015-1025

Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications.

Nilsson C; Linde F; Hulegårdh E; Garelius H; Lazarevic V; Antunovic P; Cammenga J; Deneberg S; Eriksson A; Jädersten M; Björkvall CK; Möllgård L; Wennström L; Ölander E; Höglund M; Juliusson G; Lehmann S
Article: SCIENCE IMMUNOLOGY. 2022;7(78):eadd3330

Notch-dependent cooperativity between myeloid lineages promotes Langerhans cell histiocytosis pathology.

Kvedaraite E; Milne P; Khalilnezhad A; Chevrier M; Sethi R; Lee HK; Hagey DW; von Bahr Greenwood T; Mouratidou N; Jädersten M; Lee NYS; Minnerup L; Tan Y; Dutertre C-A; Benac N; Hwang YY; Lum J; Loh AHP; Jansson J; Teng KWW; Khalilnezhad S; Xu W; Resteu A; Tey HL; Guan NL; Larbi A; Howland SW; Arnell H; Andaloussi SEL; Braier J; Rassidakis G; Galluzzo L; Dzionek A; Henter J-I; Chen J; Collin M; Ginhoux F
Article: JOURNAL OF INTERNAL MEDICINE. 2022;292(6):925-940

Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial.

Jädersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzén S; Bohlin A; Arnroth C; Erkers T; Seashore-Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Östling P; Schinazi RF; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis GZ; Höglund M; Henter J-I; Herold N
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2022;198(4):721-728

Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma.

Sveijer M; von Bahr Greenwood T; Jädersten M; Kvedaraite E; Zetterberg H; Blennow K; Lourda M; Gavhed D; Henter J-I
Article: HAEMATOLOGICA. 2022;107(7):1528-1537

A risk score based on real-world data to predict early death in acute promyelocytic leukemia.

Österroos A; Maia T; Eriksson A; Jädersten M; Lazarevic V; Wennström L; Antunovic P; Cammenga J; Deneberg S; Lorenz F; Möllgård L; Uggla B; Ölander E; Aguiar E; Trigo F; Höglund M; Juliusson G; Lehmann S
Article: BONE MARROW TRANSPLANTATION. 2022;57(2):191-197

Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial.

Walladbegi J; Henriksson R; Tavelin B; Svanberg A; Larfors G; Jädersten M; Schjesvold F; Mahdi A; Garming Legert K; Peterson DE; Jontell M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2021;27(12):991.e1-991.e9

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population.

Wedge E; Hansen JW; Dybedal I; Creignou M; Ejerblad E; Lorenz F; Werlenius O; Ungerstedt J; Holm MS; Nilsson L; Kittang AO; Antunovic P; Rohon P; Andersen MK; Papaemmanuil E; Bernard E; Jädersten M; Hellström-Lindberg E; Grønbæk K; Ljungman P; Friis LS
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2021;107(2):219-228

Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes.

Larfors G; Moreno Berggren D; Garelius H; Jädersten M; Nilsson L; Rasmussen B; Ejerblad E
Article: LEUKEMIA & LYMPHOMA. 2021;62(8):1973-1981

Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study.

Rosso A; Juliusson G; Lorenz F; Lehmann S; Derolf Å; Deneberg S; Jädersten M; Antunovic P; Cammenga J; Möllgård L; Wennström L; Ölander E; Ehinger M; Fogelstrand L; Höglund M; Lazarevic VL
Article: NATURE COMMUNICATIONS. 2021;12(1):2474

A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia.

Docking TR; Parker JDK; Jädersten M; Duns G; Chang L; Jiang J; Pilsworth JA; Swanson LA; Chan SK; Chiu R; Nip KM; Mar S; Mo A; Wang X; Martinez-Høyer S; Stubbins RJ; Mungall KL; Mungall AJ; Moore RA; Jones SJM; Birol İ; Marra MA; Hogge D; Karsan A
Article: ACTA PAEDIATRICA. 2021;110(4):1315-1321

Patients with both Langerhans cell histiocytosis and Crohn's disease highlight a common role of interleukin-23.

Kvedaraite E; Lourda M; Han H; Tesi B; Mitchell J; Ideström M; Mouratidou N; Rassidakis G; von Bahr Greenwood T; Cohen-Aubart F; Jädersten M; Åkefeldt SO; Svensson M; Kannourakis G; Bryceson YT; Haroche J; Henter J-I
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(3):474-483

Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.

Moreno Berggren D; Kjellander M; Backlund E; Engvall M; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ungerstedt J; Ejerblad E
Article: NATURE MEDICINE. 2020;26(10):1549-1556

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Solé F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jädersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Elias HK; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellström-Lindberg E; Ogawa S; Papaemmanuil E
Article: NATURE CELL BIOLOGY. 2020;22(5):526-533

Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome.

Martinez-Høyer S; Deng Y; Parker J; Jiang J; Mo A; Docking TR; Gharaee N; Li J; Umlandt P; Fuller M; Jädersten M; Kulasekararaj A; Malcovati L; List AF; Hellström-Lindberg E; Platzbecker U; Karsan A
Article: BLOOD ADVANCES. 2020;4(6):1094-1101

The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting.

Juliusson G; Jädersten M; Deneberg S; Lehmann S; Möllgård L; Wennström L; Antunovic P; Cammenga J; Lorenz F; Ölander E; Lazarevic VL; Höglund M
Article: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2019;8:7

The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994-2016.

Carlsten M; Jädersten M; Hellström A; Littmann K; Melén CM; Junlén HR; Sonnevi K; Ljungman P; Björkstrand B; Wahlin BE
Article: PLOS ONE. 2019;14(2):e0212812

PCR with electrospray ionization-mass spectrometry on bronchoalveolar lavage for detection of invasive mold infections in hematological patients.

Krifors A; Özenci V; Ullberg M; Ackefors M; Jädersten M; Strålin K; Blennow O
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;181(5):614-627

Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.

Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
Article: HAEMATOLOGICA. 2017;102(3):498-508

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.

Scharenberg C; Giai V; Pellagatti A; Saft L; Dimitriou M; Jansson M; Jädersten M; Grandien A; Douagi I; Neuberg DS; LeBlanc K; Boultwood J; Karimi M; Jacobsen SEW; Woll PS; Hellström-Lindberg E
Article: ONCOTARGET. 2016;7(16):22103-22115

Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.

Tobiasson M; McLornan DP; Karimi M; Dimitriou M; Jansson M; Ben Azenkoud A; Jädersten M; Lindberg G; Abdulkadir H; Kulasekararaj A; Ungerstedt J; Lennartsson A; Ekwall K; Mufti GJ; Hellström-Lindberg E
Article: BLOOD. 2015;126(2):233-241

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.

Malcovati L; Karimi M; Papaemmanuil E; Ambaglio I; Jädersten M; Jansson M; Elena C; Gallì A; Walldin G; Della Porta MG; Raaschou-Jensen K; Travaglino E; Kallenbach K; Pietra D; Ljungström V; Conte S; Boveri E; Invernizzi R; Rosenquist R; Campbell PJ; Cazzola M; Hellström Lindberg E
Article: NATURE COMMUNICATIONS. 2015;6:5901

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.

Gerstung M; Pellagatti A; Malcovati L; Giagounidis A; Porta MGD; Jädersten M; Dolatshad H; Verma A; Cross NCP; Vyas P; Killick S; Hellström-Lindberg E; Cazzola M; Papaemmanuil E; Campbell PJ; Boultwood J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2013;31(28):3557-3564

Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.

Pellagatti A; Benner A; Mills KI; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jädersten M; Verma A; McDonald E-J; Killick S; Hellström-Lindberg E; Bullinger L; Wainscoat JS; Boultwood J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2013;31(21):2662-2670

Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.

Koreth J; Pidala J; Perez WS; Deeg HJ; Garcia-Manero G; Malcovati L; Cazzola M; Park S; Itzykson R; Ades L; Fenaux P; Jadersten M; Hellstrom-Lindberg E; Gale RP; Beach CL; Lee SJ; Horowitz MM; Greenberg PL; Tallman MS; DiPersio JF; Bunjes D; Weisdorf DJ; Cutler C
Article: HAEMATOLOGICA. 2011;96(7):963-971

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.

Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
Article: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(15):1971-1979

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

Jädersten M; Saft L; Smith A; Kulasekararaj A; Pomplun S; Göhring G; Hedlund A; Hast R; Schlegelberger B; Porwit A; Hellström-Lindberg E; Mufti GJ
Article: LEUKEMIA. 2010;24(9):1607-1616

Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome.

Carlsten M; Baumann BC; Simonsson M; Jädersten M; Forsblom A-M; Hammarstedt C; Bryceson YT; Ljunggren H-G; Hellström-Lindberg E; Malmberg K-J
Article: LEUKEMIA. 2010;24(4):756-764

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.

Pellagatti A; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jädersten M; Killick S; Verma A; Norbury CJ; Hellström-Lindberg E; Wainscoat JS; Boultwood J
Article: HAEMATOLOGICA. 2009;94(12):1762-1766

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.

Jädersten M; Saft L; Pellagatti A; Göhring G; Wainscoat JS; Boultwood J; Porwit A; Schlegelberger B; Hellström-Lindberg E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2009;146(1):86-90

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.

Pellagatti A; Marafioti T; Paterson JC; Malcovati L; Della Porta MG; Jädersten M; Pushkaran B; George TI; Arber DA; Killick S; Giagounidis A; Hellström-Lindberg E; Cazzola M; Wainscoat JS; Boultwood J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(21):3607-3613

Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.

Jädersten M; Malcovati L; Dybedal I; Della Porta MG; Invernizzi R; Montgomery SM; Pascutto C; Porwit A; Cazzola M; Hellström-Lindberg E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2008;142(1):57-64

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.

Pellagatti A; Hellström-Lindberg E; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jädersten M; Killick S; Fidler C; Cazzola M; Wainscoat JS; Boultwood J
Article: PLOS ONE. 2008;3(4):e1970

The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts.

Boultwood J; Pellagatti A; Nikpour M; Pushkaran B; Fidler C; Cattan H; Littlewood TJ; Malcovati L; Della Porta MG; Jädersten M; Killick S; Giagounidis A; Bowen D; Hellström-Lindberg E; Cazzola M; Wainscoat JS
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2007;139(4):578-589

Gene expression profiling of CD34+ cells in patients with the 5q- syndrome.

Boultwood J; Pellagatti A; Cattan H; Lawrie CH; Giagounidis A; Malcovati L; Della Porta MG; Jädersten M; Killick S; Fidler C; Cazzola M; Hellström-Lindberg E; Wainscoat JS
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2007;104(27):11406-11411

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.

Pellagatti A; Jädersten M; Forsblom A-M; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
Article: CANCER CONTROL. 2006;13 Suppl:17-25

Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States.

Goss TF; Szende A; Schaefer C; Totten PJ; Knight R; Jädersten M; Hellström-Lindberg E; List AF
Article: CLINICAL CANCER RESEARCH. 2005;11(17):6291-6299

Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations.

Tehranchi R; Fadeel B; Schmidt-Mende J; Forsblom A-M; Emanuelsson E; Jadersten M; Christensson B; Hast R; Howe RB; Samuelsson J; Zhivotovsky B; Hellström-Lindberg E
Show more

All other publications

Editorial comment: HAEMATOLOGICA. 2023;108(7):1968-1971

Omalizumab alleviates pruritus in myeloproliferative neoplasms.

Landtblom AR; Ungerstedt J; Hedlund A; Tobiasson M; Deneberg S; Jädersten M
Letter: BLOOD ADVANCES. 2022;6(16):4705-4709

The extent of residual WT HSPCs is associated with the degree of anemia in patients with SF3B1-mutated MDS-RS.

Hofman IJF; Mortera-Blanco T; Moura PL; Vestlund J; Larsson SV; Elvarsdottir EM; Walldin G; Tobiasson M; Sander B; Dimitriou M; Jacobsen S-EW; Woll PS; Jädersten M; Hellström-Lindberg E
Letter: LEUKEMIA. 2022;36(5):1436-1439

"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".

Rasmussen B; Göhring G; Bernard E; Nilsson L; Tobiasson M; Jädersten M; Garelius H; Dybedal I; Grønbaek K; Ejerblad E; Lorenz F; Flogegård M; Marcher CW; Öster Fernström A; Cavelier L; Papaemmanuil E; Ebeling F; Kittang AO; Nørgaard JM; Saft L; Möllgård L; Hellström-Lindberg E
Letter: LEUKEMIA & LYMPHOMA. 2022;63(3):755-758

Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.

Jädersten M; Boriskina K; Lindholm C; Weström S; Cavelier L; Hellström-Lindberg E; Mielke S; Tobiasson M
Corrigendum: NATURE MEDICINE. 2021;27(5):927

Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Solé F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jädersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Elias HK; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellström-Lindberg E; Ogawa S; Papaemmanuil E
Corrigendum: NATURE MEDICINE. 2021;27(3):562

Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Solé F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jädersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellström-Lindberg E; Ogawa S; Papaemmanuil E
Letter: BLOOD. 2019;134(18):1558-1561

Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period.

Juliusson G; Hagberg O; Lazarevic VL; Ölander E; Antunovic P; Cammenga J; Wennström L; Möllgård L; Brune M; Jädersten M; Deneberg S; Lehmann S; Derolf ÅR; Höglund M
Meeting abstract: BLOOD. 2018;132:176

Resistance to Lenalidomide in Del(5q) MDS Is Mediated By Inhibition of Drug-Induced Megakaryocytic Differentiation

Martinez-Hoyer S; Mo A; Deng D; Jiang J; Docking R; Li J; Chan S; Umlandt P; Fuller M; Jadersten M; Hellstrom-Lindberg E; Platzbecker U; Parker J; Karsan A
Meeting abstract: LEUKEMIA RESEARCH. 2015;39:S153

DEVELOPMENT AND IMPLEMENTATION OF A NEW BIOBANK SYSTEM

Jansson M; Walldin G; Ben Azenkoud A; Dimitriou M; Karimi M; Tobiasson M; Jadersten M; Tapia J; Lindberg EH
Meeting abstract: BLOOD. 2013;122(21):2779

Association Between Gene Expression Profiles and Commonly Mutated Genes In The Hematopoietic Stem Cells Of Patients With Myelodysplastic Syndromes

Pellagatti A; Gerstung M; Papaemmanuil E; Malcovati L; Giagounidis A; Della Porta MG; Jadersten M; Verma A; Vyas P; Killick S; Hellstrom-Lindberg E; Cazzola M; Campbell PJ; Boultwood J
Meeting abstract: BLOOD. 2011;118(21):56-57

A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS

Koreth J; Pidala J; Perez WS; Deeg HJ; Garcia-Manero G; Malcovati L; Cazzola M; Park S; Itzykson R; Ades L; Fenaux P; Jaedersten M; Hellstrom-Lindberg E; Gale RP; Beach CL; Greenberg PL; Tallman MS; DiPersio JF; Bunjes D; Weisdorf DJ; Cutler CS
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2011;155(2):272-274

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.

Pellagatti A; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jädersten M; Killick S; Vyas P; Hellström-Lindberg E; Wainscoat JS; Boultwood J
Editorial comment: HAEMATOLOGICA. 2011;96(2):177-180

Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring.

Jädersten M; Karsan A
Review: EXPERIMENTAL CELL RESEARCH. 2010;316(8):1390-1396

New clues to the molecular pathogenesis of myelodysplastic syndromes.

Jädersten M; Hellström-Lindberg E
Letter: LEUKEMIA. 2010;24(5):1062-1065

Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia.

Boultwood J; Perry J; Pellagatti A; Fernandez-Mercado M; Fernandez-Santamaria C; Calasanz MJ; Larrayoz MJ; Garcia-Delgado M; Giagounidis A; Malcovati L; Della Porta MG; Jädersten M; Killick S; Hellström-Lindberg E; Cazzola M; Wainscoat JS
Editorial comment: HAEMATOLOGICA. 2010;95(3):348-351

Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.

Jädersten M
Meeting abstract: BLOOD. 2009;114(22):306

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells

Pellagatti A; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jadersten M; Killick S; Verma A; Hellstrom-Lindberg E; Wainscoat JS; Boultwood J
Meeting abstract: LEUKEMIA RESEARCH. 2009;33:S39

Expression of p53 or cytoplasmic nucleophosmine associated with increased risk of disease progression in myelodysplastic syndrome with isolated del(5q)

Jadersten M; Saft L; Garelius H; Hast R; Nilsson L; Samuelsson J; Porwit A; Hellstrom-Lindberg E
Meeting abstract: LEUKEMIA RESEARCH. 2009;33:S48

Lenalidomide abrogates the clonal advantage of del(5q) MDS stem cells via alteration of niche interactions

Scharenberg C; Jadersten M; Palmquist J; Forsblom L; Jansson M; Hellstrom-Lindberg E
Review: JOURNAL OF INTERNAL MEDICINE. 2009;265(3):307-328

Myelodysplastic syndromes: biology and treatment.

Jädersten M; Hellström-Lindberg E
Meeting abstract: LEUKEMIA RESEARCH. 2007;31:S113-S114

Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need

Jadersten M; Malcovati L; Dybedal I; Della Porta MG; Invernizzi R; Montgomery SM; Pascutto C; Porwit-MacDonald A; Cazzola M; Hellstrom-Lindberg E
Meeting abstract: LEUKEMIA RESEARCH. 2007;31:S35

Expression profiling of CD34+cells in patients with myelodysplastic syndromes:: differences between early and advanced cases and analysis of apoptosis-related genes

Pellagatti A; Cazzola M; Giagounidis A; Malcovati L; Della Porta MG; Jadersten M; Killick S; Fidler C; Cattan H; Bowen D; Aul C; Hellstrom-Lindberg E; Wainscoat JS; Boultwood J
Meeting abstract: BLOOD. 2006;108(11):742A

Expression profiling of CD34+cells in patients with myelodysplastic syndromes:: Involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype.

Pellagatti A; Cazzola M; Giagounidis A; Malcovati L; Della Porta MG; Jadersten M; Killick S; Fidler C; Oscier D; Bowen D; Aul C; Helistrom-Lindberg E; Wainscoat JS; Boultwood J
Published conference paper: BLOOD. 2005;106(3):803-811

Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.

Jädersten M; Montgomery SM; Dybedal I; Porwit-MacDonald A; Hellström-Lindberg E
Show more

Employments

Affiliated to Research, Department of Medicine, Huddinge, Karolinska Institutet, 2023-2026

Degrees and Education

Degree Of Doctor Of Philosophy, Department of Medicine, Huddinge, Karolinska Institutet, 2008
University Medical Degree, Karolinska Institutet, 2000

About me

Research

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI